Cargando…

Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2

The lack of therapeutic options to fight Covid-19 has contributed to the current global pandemic. Despite the emergence of effective vaccines, development of broad-spectrum antiviral treatment remains a significant challenge, in which antimicrobial photodynamic therapy (aPDT) may play a role, especi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pires, Layla, Wilson, Brian C., Bremner, Rod, Lang, Amanda, Larouche, Jeremie, McDonald, Ryan, Pearson, Joel D., Trcka, Daniel, Wrana, Jeff, Wu, James, Whyne, Cari M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400568/
https://www.ncbi.nlm.nih.gov/pubmed/36002557
http://dx.doi.org/10.1038/s41598-022-18513-0
_version_ 1784772769133625344
author Pires, Layla
Wilson, Brian C.
Bremner, Rod
Lang, Amanda
Larouche, Jeremie
McDonald, Ryan
Pearson, Joel D.
Trcka, Daniel
Wrana, Jeff
Wu, James
Whyne, Cari M.
author_facet Pires, Layla
Wilson, Brian C.
Bremner, Rod
Lang, Amanda
Larouche, Jeremie
McDonald, Ryan
Pearson, Joel D.
Trcka, Daniel
Wrana, Jeff
Wu, James
Whyne, Cari M.
author_sort Pires, Layla
collection PubMed
description The lack of therapeutic options to fight Covid-19 has contributed to the current global pandemic. Despite the emergence of effective vaccines, development of broad-spectrum antiviral treatment remains a significant challenge, in which antimicrobial photodynamic therapy (aPDT) may play a role, especially at early stages of infection. aPDT of the nares with methylene blue (MB) and non-thermal light has been successfully utilized to inactivate both bacterial and viral pathogens in the perioperative setting. Here, we investigated the effect of MB-aPDT to inactivate human betacoronavirus OC43 and SARS-CoV-2 in vitro and in a proof-of-principle COVID-19 clinical trial to test, in a variety of settings, the practicality, technical feasibility, and short-term efficacy of the method. aPDT yielded inactivation of up to 6-Logs in vitro, as measured by RT-qPCR and infectivity assay. From a photo-physics perspective, the in vitro results suggest that the response is not dependent on the virus itself, motivating potential use of aPDT for local destruction of SARS-CoV-2 and its variants. In the clinical trial we observed variable effects on viral RNA in nasal-swab samples as assessed by RT-qPCR attributed to aPDT-induced RNA fragmentation causing falsely-elevated counts. However, the viral infectivity in clinical nares swabs was reduced in 90% of samples and undetectable in 70% of samples. This is the first demonstration based on quantitative clinical viral infectivity measurements that MB-aPDT is a safe, easily delivered and effective front-line technique that can reduce local SARS-CoV-2 viral load.
format Online
Article
Text
id pubmed-9400568
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-94005682022-08-25 Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2 Pires, Layla Wilson, Brian C. Bremner, Rod Lang, Amanda Larouche, Jeremie McDonald, Ryan Pearson, Joel D. Trcka, Daniel Wrana, Jeff Wu, James Whyne, Cari M. Sci Rep Article The lack of therapeutic options to fight Covid-19 has contributed to the current global pandemic. Despite the emergence of effective vaccines, development of broad-spectrum antiviral treatment remains a significant challenge, in which antimicrobial photodynamic therapy (aPDT) may play a role, especially at early stages of infection. aPDT of the nares with methylene blue (MB) and non-thermal light has been successfully utilized to inactivate both bacterial and viral pathogens in the perioperative setting. Here, we investigated the effect of MB-aPDT to inactivate human betacoronavirus OC43 and SARS-CoV-2 in vitro and in a proof-of-principle COVID-19 clinical trial to test, in a variety of settings, the practicality, technical feasibility, and short-term efficacy of the method. aPDT yielded inactivation of up to 6-Logs in vitro, as measured by RT-qPCR and infectivity assay. From a photo-physics perspective, the in vitro results suggest that the response is not dependent on the virus itself, motivating potential use of aPDT for local destruction of SARS-CoV-2 and its variants. In the clinical trial we observed variable effects on viral RNA in nasal-swab samples as assessed by RT-qPCR attributed to aPDT-induced RNA fragmentation causing falsely-elevated counts. However, the viral infectivity in clinical nares swabs was reduced in 90% of samples and undetectable in 70% of samples. This is the first demonstration based on quantitative clinical viral infectivity measurements that MB-aPDT is a safe, easily delivered and effective front-line technique that can reduce local SARS-CoV-2 viral load. Nature Publishing Group UK 2022-08-24 /pmc/articles/PMC9400568/ /pubmed/36002557 http://dx.doi.org/10.1038/s41598-022-18513-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Pires, Layla
Wilson, Brian C.
Bremner, Rod
Lang, Amanda
Larouche, Jeremie
McDonald, Ryan
Pearson, Joel D.
Trcka, Daniel
Wrana, Jeff
Wu, James
Whyne, Cari M.
Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2
title Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2
title_full Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2
title_fullStr Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2
title_full_unstemmed Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2
title_short Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2
title_sort translational feasibility and efficacy of nasal photodynamic disinfection of sars-cov-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400568/
https://www.ncbi.nlm.nih.gov/pubmed/36002557
http://dx.doi.org/10.1038/s41598-022-18513-0
work_keys_str_mv AT pireslayla translationalfeasibilityandefficacyofnasalphotodynamicdisinfectionofsarscov2
AT wilsonbrianc translationalfeasibilityandefficacyofnasalphotodynamicdisinfectionofsarscov2
AT bremnerrod translationalfeasibilityandefficacyofnasalphotodynamicdisinfectionofsarscov2
AT langamanda translationalfeasibilityandefficacyofnasalphotodynamicdisinfectionofsarscov2
AT larouchejeremie translationalfeasibilityandefficacyofnasalphotodynamicdisinfectionofsarscov2
AT mcdonaldryan translationalfeasibilityandefficacyofnasalphotodynamicdisinfectionofsarscov2
AT pearsonjoeld translationalfeasibilityandefficacyofnasalphotodynamicdisinfectionofsarscov2
AT trckadaniel translationalfeasibilityandefficacyofnasalphotodynamicdisinfectionofsarscov2
AT wranajeff translationalfeasibilityandefficacyofnasalphotodynamicdisinfectionofsarscov2
AT wujames translationalfeasibilityandefficacyofnasalphotodynamicdisinfectionofsarscov2
AT whynecarim translationalfeasibilityandefficacyofnasalphotodynamicdisinfectionofsarscov2